US Patent

US12144801 — Methods and compositions for treatment of epileptic disorders

Method of Use · Assigned to Ovid Therapeutics Inc · Expires 2037-08-10 · 11y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods and compositions for treating epileptic disorders using allosteric modulators and/or gaboxadol.

USPTO Abstract

Use of allosteric modulators and/or gaboxadol for the treatment of epileptic disorders in a subject in need thereof.

Drugs covered by this patent

Ztalmy (GANAXOLONE) · Marinus

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4034`	—	Ztalmy

Patent Metadata

Patent number: US12144801
Jurisdiction: US
Classification: Method of Use
Expires: 2037-08-10
Drug substance claim: No
Drug product claim: No
Assignee: Ovid Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.